SCHEMBL23217613

SCHEMBL23217613

CCOC(=O)Cc1ccccc1OCc1cc(-c2csc(C(C)=O)n2)c2occc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 10/20 0.53
BAX Q07812 1/20 0.38
ALDH1A1 P00352 4/20 0.37
MAPT P10636 4/20 0.37
TBXAS1 P24557 1/20 0.36
PKM P14618 2/20 0.36
PRMT5 O14744 1/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
HTT P42858 1/20 0.34
TDP1 Q9NUW8 2/20 0.33
KDM4E B2RXH2 1/20 0.33
HPGD P15428 1/20 0.33
MEN1 O00255 1/20 0.33
GLA P06280 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30009883 1.00 CFD (0.53) CFDBAXALDH1A1MAPTTBXAS1
SCHEMBL30010424 0.89 CFD (0.53) CFDBAXALDH1A1MAPTTBXAS1
SCHEMBL29672942 0.89 CFD (0.53) CFDBAXALDH1A1MAPTTBXAS1
SCHEMBL23217192 0.89 CFD (0.53) CFDBAXALDH1A1MAPTTBXAS1
SCHEMBL28772726 0.88 CFD (0.47) CFDBAXALDH1A1MAPTTBXAS1
SCHEMBL23217449 0.88 CFD (0.55) CFDBAXALDH1A1MAPTTBXAS1
SCHEMBL30010615 0.88 CFD (0.55) CFDBAXALDH1A1MAPTTBXAS1
SCHEMBL23241513 0.88 CFD (0.46) CFDBAXALDH1A1MAPTTBXAS1
SCHEMBL28772701 0.88 CFD (0.46) CFDBAXALDH1A1MAPTTBXAS1
SCHEMBL28943912 0.87 CFD (0.48) CFDBAXALDH1A1MAPTTBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-09-04 US disclosed
EP-4041717-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114555570-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-27 CN disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885BAX 1560/4885ALDH1A1 3388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.